Lung Cancer Clinical Trial

Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous Radiotherapy

Summary

PURPOSE: This trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and radiation therapy for patients with locally advanced Non-Small Cell Lung Cancer (NSCLC) with no prior chemotherapy or radiation therapy treatment. Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria.

WHAT IS SATRAPLATIN: Satraplatin is an oral, investigational anticancer drug that is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

RATIONALE: Intravenously administered platinum-based drugs are currently used in combination with radiation therapy in the treatment of patients with locally advanced NSCLC. The purpose of this Phase I trial is to determine a tolerable dose and schedule for the oral platinum drug (satraplatin) when given to NSCLC patients throughout the course of their radiotherapy treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Locally advanced or medically inoperable NSCLC (stage II or III)
ECOG performance status score 0-2
Adequate bone marrow, liver, and pulmonary functions
Life expectancy > three months.

Exclusion Criteria:

Prior malignancy
Serious concurrent uncontrolled medical disorder.
Uncontrolled or significant cardiovascular disease
History of mastectomy
Pregnant or breast-feeding patients are not eligible
Prior radiotherapy to the primary tumor site or cytotoxic chemotherapy

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT00093132

Recruitment Status:

Terminated

Sponsor:

Agennix

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Southwestern Medical Center
Dallas Texas, 75390, United States

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 1

Estimated Enrollment:

20

Study ID:

NCT00093132

Recruitment Status:

Terminated

Sponsor:


Agennix

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider